Recombinant Human Platelet-Activating Factor Acetylhydrolase Reduces the Frequency of Diabetes In the Diabetes-Prone BB Rat

摘要

Platelet-activating factor (PAF) has been implicated in the development of type 1 diabetes. Our previous stud- ies have suggested that PAF inhibitors reduce insulitis and the frequency of diabetes in BB rats. In this study, serum PAF levels were reduced to address the hypoth- esis that PAF is important for the development of insulitis. From the age of 35 days on, DP-BB rats were treated with human recombinant PAF acetylhydrolase (rPAF-AH), which efficiently inactivates PAF. Our data indicate that intraperitoneal injections of rPAF-AH reduce the incidence of diabetes in the DP-BB rat.